Heart and Vessels

, Volume 31, Issue 1, pp 80–87 | Cite as

Characterization of cardiac oxidative stress levels in patients with atrial fibrillation

  • Ayako Okada
  • Yuichiro KashimaEmail author
  • Takeshi Tomita
  • Takahiro Takeuchi
  • Kazunori Aizawa
  • Masafumi Takahashi
  • Uichi Ikeda
Original Article


Atrial fibrillation (AF) is associated with oxidative stress and elevated brain natriuretic peptide (BNP) levels. However, the exact cardiac origin of oxidative stress and its association with BNP levels in AF patients remain unclear. Therefore, we investigated the chamber-specific plasma oxidative stress levels in patients with paroxysmal AF (PAF) and persistent AF (PSAF). Diacron-reactive oxygen metabolite (dROM) levels were measured in patients with PAF (n = 50) and PSAF (n = 35) at different cardiac sites before ablation and in peripheral vein 3 months after ablation. For all sites, dROM levels were higher in PSAF patients than in PAF patients; the levels were the highest in the coronary sinus at 429.0 (interquartile range: 392.0–449.0) vs. 374.0 (357.0–397.8) Carratelli units (P < 0.05). dROM levels in the coronary sinus were related to the BNP levels (r = 0.436, P < 0.001). Furthermore, the reduction in the peripheral dROM levels was related to that in the peripheral BNP levels in patients with symptomatic improvement (r = 0.473, P < 0.001). Cardiac oxidative stress may either be a cause or consequence of prolonged AF, and cardiac oxidative stress levels correlated with BNP levels, though a possible source of oxidative stress in AF patients may be systemic circulation.


Atrial fibrillation Oxidative stress Brain natriuretic peptide Ablation 



We thank Minako Aono, Yuka Ichihara, Kazuko Misawa, Kayo Kobayashi, and Mebae Kobayashi for their excellent technical assistance.

Conflict of interest

The authors have no conflicts of interest and no sources of financial support to declare.


  1. 1.
    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society (2006) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257–354Google Scholar
  2. 2.
    Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219–226PubMedCrossRefGoogle Scholar
  3. 3.
    Yang KC, Dudley SC Jr (2013) Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. Circulation 128:1724–1726PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, Weiss JN, Cai H (2013) Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 62:72–79PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028PubMedCrossRefGoogle Scholar
  6. 6.
    Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi: 10.1007/s00380-013-0400-8 Google Scholar
  7. 7.
    Sovari AA, Dudley SC (2012) Antioxidant therapy for atrial fibrillation: lost in translation? Heart 98:1615–1616PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Van Wagoner DR (2008) Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 52:306–313PubMedCrossRefGoogle Scholar
  9. 9.
    Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR (2001) Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89:E32–E38PubMedCrossRefGoogle Scholar
  10. 10.
    Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S (2004) Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110:2313–2319PubMedCrossRefGoogle Scholar
  11. 11.
    Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr (2007) Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53:1652–1657PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Shimano M, Shibata R, Inden Y, Yoshida N, Uchikawa T, Tsuji Y, Murohara T (2009) Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 6:935–940PubMedCrossRefGoogle Scholar
  13. 13.
    Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174–180PubMedCrossRefGoogle Scholar
  14. 14.
    Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B (2008) Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51:68–74PubMedCrossRefGoogle Scholar
  15. 15.
    Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274PubMedCrossRefGoogle Scholar
  16. 16.
    McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159–163PubMedCrossRefGoogle Scholar
  17. 17.
    Gould PA, Gula LJ, Bhayana V, Subbiah RN, Bentley C, Yee R, Klein GJ, Krahn AD, Skanes AC (2010) Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation. Circ Arrhythm Electrophysiol 3:18–23PubMedCrossRefGoogle Scholar
  18. 18.
    Kurosaki K, Tada H, Hashimoto T, Ito S, Miyaji K, Naito S, Oshima S, Taniguchi K (2007) Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. Circ J 71:313–320PubMedCrossRefGoogle Scholar
  19. 19.
    Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMedCrossRefGoogle Scholar
  20. 20.
    Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535PubMedCrossRefGoogle Scholar
  21. 21.
    von Lüdinghausen M, Ohmachi N, Besch S, Mettenleiter A (1995) Atrial veins of the human heart. Clin Anat 8:169–189CrossRefGoogle Scholar
  22. 22.
    Kim BJ, Hwang SJ, Sung KC, Kim BS, Kang JH, Lee MH, Park JR (2007) Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. Int J Cardiol 118:145–150PubMedCrossRefGoogle Scholar
  23. 23.
    Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96PubMedCrossRefGoogle Scholar
  24. 24.
    Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Bergler-Klein J, Binder T, Wojta J, Gössinger HD (2012) Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 101:217–225PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Ayako Okada
    • 1
  • Yuichiro Kashima
    • 1
    Email author
  • Takeshi Tomita
    • 1
  • Takahiro Takeuchi
    • 1
  • Kazunori Aizawa
    • 1
  • Masafumi Takahashi
    • 2
  • Uichi Ikeda
    • 1
  1. 1.Department of Cardiovascular MedicineShinshu University School of MedicineMatsumotoJapan
  2. 2.Division of Bio-ImagingJichi Medical UniversityTochigiJapan

Personalised recommendations